Get the Stockscreener App
15.06
0.82%
0.19
Y Mabs Therapeutics Inc stock is traded at $15.06, with a volume of 159.97K.
It is up +0.82% in the last 24 hours and up +5.88% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$14.87
Open:
$14.77
24h Volume:
159.97K
Relative Volume:
0.65
Market Cap:
$673.90M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-16.92
EPS:
-0.89
Net Cash Flow:
$-27.23M
1W Performance:
+1.71%
1M Performance:
+5.88%
6M Performance:
-12.58%
1Y Performance:
+174.08%
1-Day Range:
$14.77
$15.22
1-Week Range:
$14.19
$15.22
52-Week Range:
$4.69
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
212-847-9841
Address
230 PARK AVENUE, NEW YORK, NY
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com UK
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Objective long/short (YMAB) Report - Stock Traders Daily
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail
13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC - Defense World
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers (NASDAQ:YMAB) - Seeking Alpha
AQR Capital Management LLC Makes New Investment in TreeHouse Foods, Inc. (NYSE:THS) - Defense World
Cubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Cubist Systematic Strategies LLC Takes Position in Seer, Inc. (NASDAQ:SEER) - Defense World
Summit Materials, Inc. (NYSE:SUM) Shares Bought by SG Americas Securities LLC - Defense World
Pediatric Oncology Drugs Market Size, Share, Growth Insights - openPR
(YMAB) On The My Stocks Page - Stock Traders Daily
Millennium Management LLC Boosts Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.7%Still a Buy? - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Cubist Systematic Strategies LLC Sells 71,189 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Squarepoint Ops LLC Acquires 74,452 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Squarepoint Ops LLC Has $1.53 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Long Term Trading Analysis for (YMAB) - Stock Traders Daily
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.1%Here's What Happened - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.1% - Defense World
Point72 Asset Management L.P. Sells 1,168,155 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.5% - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.14 Average PT from Analysts - MarketBeat
Y-mAbs to Participate in Upcoming Investor Conferences in October - The Manila Times
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces pivotal year - Investing.com
Radiotheranostics Revolution: What to Expect from the 2024 Global Market As Discussed In New Market Researc... - WhaTech
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Jamf (NASDAQ:JAMF) Shares Gap Down to $18.70 - MarketBeat
Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India
Jamf (NASDAQ:JAMF) Earns “Market Outperform” Rating from JMP Securities - Defense World
Jamf's (JAMF) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
272 Capital LP Acquires 44,486 Shares of Jamf Holding Corp. (NASDAQ:JAMF) - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - MarketBeat
Stock Surge: Y-Mabs Therapeutics Inc (YMAB) Closes at 13.73, Marking a -1.93 Increase/Decrease - The Dwinnex
Examining the Potential Price Growth of Jamf Holding Corp (JAMF) - Knox Daily
How To Trade (YMAB) - Stock Traders Daily
Nothing is Better Than Y-Mabs Therapeutics Inc (YMAB) stock at the moment - SETE News
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 13 '24 |
Sale |
13.47 |
65,000 |
875,550 |
97,681 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 16 '24 |
Sale |
12.97 |
30,000 |
389,100 |
67,681 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):